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de la Timone and 4) Service de chirurgie orthopédique, Hôpital Saint Marguerite, Marseille, FranceAbstractStreptococcal bone and joint infections are less common than staphylococcal cases. Few studies have reported the cases with well-identiﬁed
Streptococcus species. Their clinical features and prognosis are not clearly known to date. Moreover, no treatment regimen has yet been
clariﬁed. We reviewed the streptococcal bone and joint infection cases managed in our centres from January 2009 to December 2013.
We described the epidemiology, clinical and microbiologic characteristics, treatment approach and outcome. Among the 93 cases, 83% of
patients were men with a median age of 60 years, and 90% of patients had comorbidities or risk factors. Bacteraemia occurred in 14% of
cases. Serious complications occurred in six patients, including severe sepsis (two cases) and infective endocarditis (two cases).
Orthopaedic device infections were observed in 35% of cases, including 17 patients with internal osteosynthesis device infection, 14 with
prosthetic joint infection and three with vertebral osteosynthesis device infection. The median time between orthopaedic device
implantation and onset of infection was 447 days. Fourteen species of Streptococcus were identiﬁed, including 97 isolates using matrix-
assisted laser desorption/ionization time-of-ﬂight mass spectrometry and three isolates using molecular identiﬁcation. The ﬁve most
represented species included S. agalactiae (37%), S. dysgalactiae (12%), S. anginosus (11%), S. constellatus (10%) and S. pneumoniae (9%).
Streptococci isolates were susceptible to amoxicillin, with the exception of one S. mitis isolate. Remission 1 year after the end of
treatment was recorded in 83%. One patient died of infection; eight patients had infections that failed to respond to treatment; and
seven patients experienced relapse. Twenty patients (22%) had an unfavourable functional outcome, including 19 amputations and one
arthrodesis. Five signiﬁcant prognostic factors associated with an unfavourable clinical outcome were identiﬁed, including peripheral
neuropathy (p 0.009), peripheral arterial disease (p 0.019), diabetes mellitus (p 0.031), location in the femur (p 0.0036), location in the
foot (p 0.0475), osteitis without an orthopaedic device (p 0.041) and infection caused by S. dysgalactiae (p 0.020). The rate of poor
outcomes remains high despite the low number of Streptococcus isolates resistant to antibiotics. Some prognostic factors, such as the
presence of S. dysgalactiae, are associated with an unfavourable clinical outcome. Antibiotic regimens of streptococcal bone and joint
infections are not standardized and need to be further investigated.
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
Keywords: Arthritis, bacterial infection, bone and joint infection, human, MALDI-TOF MS, osteitis, osteomyelitis, prosthetic joint infection,
streptococci, Streptococcus
Original Submission: 5 February 2016; Revised Submission: 24 March 2016; Accepted: 25 March 2016
Article published online: 13 April 2016Ne
©
Th
httCorresponding author: P. Seng, Centre de Référence des In-
fections Ostéo-Articulaires Interrégional Sud Méditerranée, Service
des Maladies Infectieuses, Hôpital de la Conception, 147 boulevard
Baille, Marseille, France
E-mail: sengpiseth@yahoo.frw Microbe and New Infect 2016; 12: 8–17
2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice
p://dx.doi.org/10.1016/j.nmni.2016.03.009IntroductionAlthough streptococcal bone and joint infections such as
arthritis and osteomyelitis are less common than infections due
to staphylococci, their role as causative agents of bone and jointiology and Infectious Diseases
nses/by-nc-nd/4.0/)
NMNI Seng et al. Infections with streptococcal involvement 9infection remains signiﬁcant [1–5]. Previous studies of strep-
tococcal bone and joint infection have reviewed the clinical
characteristics and the outcome of streptococcal arthritis or
joint prosthesis infection by streptococcal groups classiﬁed by
Lanceﬁeld and Sherman [3–10]. Only a few studies of strep-
tococcal bone and joint infection with well-identiﬁed species
have been reported [11–15].
Identiﬁcation of Streptococcus species is difﬁcult and
constantly evolving. The current method used for identiﬁcation
relies on phenotypic conventional techniques (Gram stain,
evaluation of hemolysis, Lanceﬁeld antigen) that appear to be
less sensitive [16]. In addition, new methods have been devel-
oped to identify the Streptococcus genus, including PCR ampli-
ﬁcation of the 16S rRNA gene, which has led to a change in the
taxonomy of streptococci [17,18]. Speciﬁc nucleic acid probes
for S. pneumoniae and S. agalactiae identiﬁcation have been
developed [19]. Recently rpoB, GroEL, soda and tuf gene
sequence–based identiﬁcation has been used to identify the
species of Streptococcus anginosus groups [16,19–21].
Matrix-assisted desorption ionization–time of ﬂight mass
spectrometry (MALDI-TOF MS) identiﬁcation has been suc-
cessfully implemented in routine bacterial identiﬁcation in clinical
laboratories [22]. More recently, MALDI-TOF MS has been used
as a reliable routine identiﬁcation tool for Streptococcus species
compared to phenotypic and molecular identiﬁcation [23–25].
The objective of this study was to review the clinical char-
acteristics and outcomes of well-deﬁned monomicrobial and
polymicrobial bone and joint infections caused by Streptococcus
species managed at our referral centre for the treatment of
bone and joint infections.Materials and MethodsStudy population
This study was approved by the institutional research ethics
board, and written informed consent was provided by each
patient. We retrospectively reviewed 93 cases of streptococcal
bone and joint infection in 3931 patients (inpatients and out-
patients aged >18 years) managed in our referral centre for the
treatment of bone or joint infections from January 2009 to
December 2013. All cases were managed at four university
hospitals with 4000 beds in Marseille, France, including four
orthopaedic surgery units, two plastic surgery units and two
infectious disease units.
Streptococcal bone and joint infections were diagnosed on
the basis of medical history with clinical evidence of infection
using biological and/or radiologic compliant data, with at least
one positive culture from two or more deep samples based on
surgical procedures that excluded the contaminated bacteria, as© 2016 The Authors. Published by Elsevier Ltd on beha
This is an open access articpreviously described [26]. Prosthetic joint infection was deﬁned
when patients had Infectious Diseases Society of America or
Musculoskeletal Infection Society criteria meeting the deﬁnition
for prosthetic joint infection [27,28]. Infections involving a
prosthetic joint were classiﬁed according to the time of onset
after implantation: early infection (within 1 month) or chronic
infection (after 1 month) [29].
We recorded the patients’ medical history including
demographic characteristics, comorbidities and risk factors
associated with bone and joint infection, clinical presentation,
and type and site of infection. We then recorded the medical
and/or surgical treatment approach and the duration of relapse-
free time after treatment. We evaluated treatment success as
the remission rate at 3, 6 and 12 months after the end of
antibiotic treatment.
An unfavourable clinical outcome was deﬁned as failure to
treat, relapse or death caused by infection. Failure to treat was
deﬁned by pain and swelling of the bone or joint, wound
drainage, implant site erythema, induration or edema, joint pain,
joint effusion, fever, purulent discharge from the wound, sinus
tract drainage and persistent positive culture from deep sam-
ples based on surgical procedures during the treatment period.
Relapse was deﬁned by pain and swelling of the bone or joint,
wound drainage, implant site erythema, induration or edema,
joint pain, joint effusion, fever, purulent discharge from the
wound, sinus tract drainage and persistent positive culture from
deep samples based on surgical procedures after the end of
treatment and during follow-up examinations at the clinic. An
unfavourable functional outcome was deﬁned as amputation,
arthrodesis or severe functional deterioration.Specimen collection and microbiologic analysis
For all patients, deep samples were obtained by surgical pro-
cedures, i.e. joint ﬂuid, crushed tissue or bone biopsy samples
inoculated on 5% sheep’s blood, chocolate, Mueller-Hinton,
trypticase soy and MacConkey agar plates (bioMérieux, Marcy
l’Etoile, France) and incubated at 37°C in a 5% CO2 atmosphere
and in an anaerobic atmosphere for 10 days. Pure bacterial
cultures, obtained by picking isolated colonies, were identiﬁed
with MALDI-TOF MS and molecular methods, as previously
described [22,30]. The antibiotic susceptibilities of Streptococcus
sp. isolates were determined and interpreted according to the
recommendations of the French Society for Microbiology and
the European Committee on Antimicrobial Susceptibility Testing
(CA-SFM/EUCAST, available at http://www.sfm-microbiologie.
org/UserFiles/ﬁles/casfm/CASFM_EUCAST_V1_0_2014.pdf).
Statistical analysis
Data analyses were performed by SPSS 20.0 (IBM SPSS, Chi-
cago, IL, USA). We conducted a descriptive analysis of ourlf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 12, 8–17
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 1. Clinical relevance of 93 cases of osteoarticular







(n [ 34), n (%)
Polymicrobial
infection
(n [ 59), n (%)
Sex
Female 16 (17) 6 (18) 10 (17)
Male 77 (83) 28 (82) 49 (83)
Comorbidities and risk factors 84 (90) 25 (74) 59 (100)
Diabetes mellitus 34 (37) 10 (29) 24 (41)
Tobacco use 28 (30) 10 (29) 18 (31)
Peripheral arterial disease 27 (29) 6 (18) 21 (36)
Peripheral neuropathy 21 (23) 1 (3) 20 (34)
Malignancy 15 (16) 6 (18) 9 (15)
Haematologic malignancy 4 (4) 3 (9) 1 (2)
Solid cancer 11 (12) 3 (9) 8 (14)
Chronic liver disease 10 (11) 1 (3) 9 (15)
Immunodeﬁciency 9 (10) 5 (15) 4 (7)
Corticosteroid treatment 4 (4) 1 (3) 3 (5)
Asplenia 2 (2) 2 (6) 0
HIV infection 2 (2) 0 2 (3)
Alcoholism 7 (8) 0 7 (12)
Inﬂammatory rheumatism 5 (5) 2 (6) 3 (5)
Pneumonia 3 (3) 1 (3) 2 (3)
10 New Microbes and New Infections, Volume 12 Number C, July 2016 NMNIpopulation (chi-square test), then analysed the relapse prog-
nostic factors after medicosurgical treatment. Univariate anal-
ysis was performed ﬁrst to identify prognostic variables strongly
associated (p <0.2) with risk of relapse (proportional hazard
assumptions veriﬁed on the representation of Schönefeld resi-
dues); then multivariate analysis was performed to assess the
predictions speciﬁcally for Streptococcus species after adjusting
for signiﬁcant variables in the univariate analysis and/or risk
factors such as those reported in the literature including dia-
betes mellitus, location in the foot and polymicrobial infection
[3,4,6,31–33]. A p value of <0.05 was considered statistically
signiﬁcant. Kaplan-Meier curves were used for graphical illus-
tration. The median follow-up reverse Kaplan-Meier method
and the log-rank test were used for comparing curves sys-
tematically between variables.Intravenous drug users 2 (2) 1 (3) 1 (2)
Chronic wound 42 (45) 1 (3) 41 (69)
Closed fracture 22 (24) 4 (12) 18 (31)
Open fracture 8 (9) 3 (9) 5 (8)
Clinical and biological presentation
ResultsLocal inﬂammation 64 (69) 22 (65) 42 (71)
Purulent discharge
inside wound
57 (61) 9 (26) 48 (81)
Fever 40 (43) 20 (59) 20 (34)
Erysipelas 13 (14) 2 (6) 11 (19)
Bacteraemia 13 (14) 6 (18) 7 (12)
Severe sepsis 3 (3) 2 (6) 1 (2)
Endocarditis 3 (3) 3 (9) 0
C-reactive protein
rate 40 mg/mL
73 (79) 28 (82) 45 (76)
Type of infection
Without orthopaedic devicea 60 (65) 17 (50) 46 (78)
Osteitis 42 (45) 4 (12) 38 (64)
Arthritis 12 (13) 8 (24) 4 (7)
Vertebral osteomyelitis 9 (10) 5 (15) 4 (7)
With orthopaedic deviceb 33 (35) 17 (50) 16 (27)
Internal osteosynthesis
device infection
17 (18) 8 (24) 9 (15)
Joint prosthesis infection 14 (15) 8 (24) 6 (10)
Vertebral osteosynthesis
device infection
3 (3) 1 (3) 2 (3)
Infection localization
Foot 31 (33) 2 (6) 29 (49)
Knee 15 (16) 9 (26) 6 (10)
Tibia 14 (15) 6 (18) 8 (14)
Vertebra 12 (13) 8 (24) 4 (7)
Hip 9 (10) 5 (15) 4 (7)
Ankle 8 (9) 4 (12) 4 (7)
Hand 4 (4) 0 4 (7)
Wrist 2 (2) 2 (6) 0
Sternoclavicular 1 (1) 1 (3) 0
Shoulder 1 (1) 1 (3) 0
Femur 1 (1) 0 (0) 1 (2)
Pelvis 2 (2) 1 (3) 1 (2)
Multiple localization 6 (6) 4 (12) 2 (3)
Orthopaedic device infection delays
Early infection (month 1) 4 (12) 1 (6) 3 (19)
Delayed infection
(months 2–6)
6 (18) 4 (24) 2 (13)
Late infection
(more than month 6)
23 (70) 12 (71) 11 (69)
aThree vertebral infections without osteosynthesis were associated with osteitis
and arthritis in one and two, respectively.
bOne vertebral osteosynthesis device infection was associated with osteitis with
internal osteosynthesis device infection.Demographics and clinical characteristics
Of the 93 patients with streptococcal bone and joint infection,
77 patients (83%) were men, yielding a male/female ratio of
4.81; median patient age was 60 years (±17 years; range, 22–92
years). Ninety percent of our patients had comorbidities and/or
risk factors. Diabetes mellitus and tobacco use were respec-
tively identiﬁed in 34 (37%) and 28 cases (30%). A history of
malignancy was observed in 15 patients (16%), including solid
cancer in 11 cases (12%) and haematologic malignancy in four
cases (4%). Nine patients (10%) were immunocompromised
involving corticosteroid treatment in four cases (4%), asplenia
in two cases (2%) and HIV infection in two cases (2%). The
following risk factors were the most important and frequently
observed: chronic wound, peripheral arterial disease, periph-
eral neuropathy and closed fracture (Table 1).
Local inﬂammation, which occurred in 64 patients (69%),
was the most frequent clinical symptom, followed by purulent
discharge inside the wound in 57 patients (61%), fever in 40
(43%) and erysipelas in 13 (14%). Bacteraemia occurred in 13
patients (14%). Serious complications occurred in six patients,
including two cases of severe sepsis and two cases of infectious
endocarditis. One case of septic shock was recorded (Table 1).
Streptococcal bone and joint infections without an ortho-
paedic device were observed in 60 patients (65%), including 42
(45%) with osteitis, 12 (13%) with arthritis and nine (10%) with
vertebra osteomyelitis. Of the 42 cases of streptococcal oste-
itis, 27 were located in the foot, including 17 cases of diabetic
foot infection and seven cases of nondiabetic foot infection
(four cases of peripheral neuropathy and three cases of pe-
ripheral arterial disease). Another 15 cases of streptococcal
osteitis were located in the tibia (six cases), knee (two cases),© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceankle (two cases), femur (two cases), hip (one case), pelvis (one
case) and hand (one case). Three cases of vertebra osteomy-
elitis without an orthopaedic device were associated with
osteitis in one case and with arthritis in two cases.
Streptococcal orthopaedic implant infections were observed
in 33 patients (35%), including 17 cases (18%) of orthopaediciology and Infectious Diseases, NMNI, 12, 8–17
nses/by-nc-nd/4.0/).
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three cases (3%) of vertebral orthopaedic device infection. One
case of vertebral orthopaedic device infection was associated
with orthopaedic device infection in the tibia. Most cases of
orthopaedic device infection (88%) were chronic infections
occurring more than 1 month after implantation (Table 1). The
median time delay between orthopaedic device implantation
and infection onset was 447 days. In total, the foot represented
the main location of osteitis (33%), followed by the knee (15%)
and tibia (15%). Six patients (5%) had multiple sites of strep-
tococcal bone and joint infection (Table 1).
Microbiologic characteristics
Fourteen species of Streptococcus from 100 streptococcal iso-
lates were identiﬁed, of which 97 strains (97%) were identiﬁed
by MALDI-TOF MS and three (3%) by molecular biology. The
ﬁve most represented species were S. agalactiae in 37 cases
(37%), S. dysgalactiae in 12 cases (12%), S. anginosus in 11 cases
(11%), S. constellatus in ten cases (10%) and S. pneumoniae in
nine cases (9%) (Fig. 1).
The two most frequent streptococcal species of the 12 cases
of streptococcal arthritis were S. agalactiae (42%) and
S. pneumoniae (33%). The four main streptococcal species
involved in the 42 cases of osteitis without an orthopaedic device
were S. agalactiae (36%), S. anginosus (17%), S. dysgalactiae (17%)
and S. constellatus (14%). The threemain species of the 17 cases of
osteitis with internal orthopaedic device infection wereFIG. 1. Distribution of Streptococcus species (A) and related bacteria (B).
© 2016 The Authors. Published by Elsevier Ltd on beha
This is an open access articS. agalactiae (41%), S. dysgalactiae (18%) and S. mitis (18%). The
two most frequent species involved in the 14 cases of joint
prosthesis infection were S. agalactiae (36%) and S. pneumoniae
(29%). S. agalactiae was the main streptococcal species (47%)
involved in the 12 cases of vertebral osteomyelitis with and
without an orthopaedic device. The three main streptococcal
species involved in the 31 bone and joint infections located in the
footwere S. agalactiae (39%), S. dysgalactiae (26%) and S. anginosus
(19%); these species were identiﬁed in the 18 cases of diabetic
foot, at 39%, 33% and 17%, respectively (Fig. 2).
Among the species of streptococci involved in bone and joint
infection, S. agalactiae was associated with haematologic ma-
lignancy (p 0.023), S. constellatus with solid cancer (p 0.016),
S. dysgalactiae with peripheral neuropathy and the foot (p 0.004
and 0.018), S. anginosus with a closed fracture (p 0.019) and
S. pneumoniae with arthritis, joint prosthesis infection and in the
hip (p 0.015, 0.027 and 0.004).
Thirty-four cases (37%) of streptococcal bone and joint
infection were monomicrobial infections; 59 cases (63%) were
associated with another bacteria species. The bone and joint
infections caused by S. agalactiae and S. pneumoniae were usually
monomicrobial infections (p 0.027 and 0.011). Arthritis and
vertebral infections without an orthopaedic device were
frequently monomicrobial infections (p 0.027 and 0.011).
Among the 59 cases of polymicrobial infection, Staphylococcus
aureus and coagulase-negative staphylococci were the main
bacterial species (Fig. 1). Polymicrobial infections werelf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 12, 8–17
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
FIG. 2. Streptococcus species distribution depending on type of infection.
12 New Microbes and New Infections, Volume 12 Number C, July 2016 NMNIcommonly observed in cases involving peripheral arterial dis-
ease, peripheral neuropathy, alcoholism, closed fractures,
chronic wounds, location in the foot, and bone and joint
infection caused by S. anginosus (p 0.001, 0.001, 0.045, 0.046,
0.0001, 0.001 and 0.006, respectively).
All streptococci isolates were susceptible to amoxicillin, with
the exception of one strain of S. mitis that demonstrated reduced
susceptibility to amoxicillin. Fifty-six streptococci isolates (48%)
demonstrated reduced susceptibility to doxycycline, seven
strains (8%) to rifampicin and six strains (9%) to gentamycin.
Medical and surgical treatment
Eighty-two patients (88%) were treated by a combination of
surgery with at least one antibiotic that was active against
Streptococcus isolates. Eleven patients (12%) received only
medical treatment, including ﬁve cases (5%) of arthritis, ﬁve
cases of osteitis without an orthopaedic device, one case of
prosthetic joint infection and two cases of vertebral osteomy-
elitis without an orthopaedic device (Table 2). It should be
noted that these two cases were of vertebral osteomyelitis
without an orthopaedic device were localized to more than one
site, i.e. one case associated with arthritis and one case with
osteitis without an orthopaedic device.
Amoxicillin therapy was provided in 55 cases (59%), rifam-
picin in 34 cases (37%), clindamycin in 23 cases (25%), quino-
lones in 20 cases (22%), cotrimoxazole in 21 cases (23%) and
ceftriaxone in 20 cases (21%). Twenty-one cases (23%) were
treated by only one antibiotic; the main antibiotics used were
amoxicillin and ceftriaxone in 12 cases and three cases,
respectively. The median dose of amoxicillin used was 9 g/day
(range, 6–12 g/day).© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceAntibiotic combinations were recorded in 72 cases (77%).
The most frequently used associated antibiotic was amoxi-
cillin–rifampicin in 24 cases (26%), followed by clindamycin–
cotrimoxazole in ten cases (11%) (Table 2). Short courses of
initial treatment with intravenous antibiotics were provided in
49 cases (53%). The mean time of antibiotic duration was 124
days (±68 days; range, 16–350 days).
Forty-four patients (47%) were treated directly by oral an-
tibiotics. Forty-nine patients (53%) were treated by intravenous
antibiotics with a mean time of intravenous antibiotic treatment
of 62 days (median, 34 ± 63 days; range, 2–238 days). Thirty-
three patients (35%) were changed secondarily to oral antibi-
otics at a mean time of 28 days (median, 18 ± 27 days; range,
2–103 days); 16 patients were treated by intravenous antibi-
otics until the end of treatment.
Surgical treatment was performed in 50 cases (83%) of bone
and joint infection without an orthopaedic device and in 32 cases
(97%) of orthopaedic device–related infection. Ten cases (83%)
of streptococcal vertebral osteomyelitis were treated with sur-
gical debridement, including establishment of vertebral osteo-
synthesis in our cases. Seven cases (58%) of streptococcal
arthritis without orthopaedic device infection were treated with
surgical debridement and ﬁve cases (42%) with antibiotic treat-
ment without surgical debridement. Thirty-seven cases (88%) of
streptococcal osteitis without orthopaedic device infection were
treated by surgery, including 21 patients with surgical debride-
ment and 18 patients with amputation. Thirteen cases (93%) of
streptococcal prosthetic joint infection were treated by surgery,
including six patients with surgical debridement with retention
and seven patients with prosthesis replacement by a two-stage
exchange strategy. All the cases of internal osteosynthesisiology and Infectious Diseases, NMNI, 12, 8–17
nses/by-nc-nd/4.0/).
TABLE 2. Treatment of 93 cases of osteoarticular infections
















Hyperbaric oxygen therapy 16 (17)
Osteoarticular infection without orthopaedic device 60 (65)
Vertebral osteomyelitis 9 (10)
Medical treatment only 2 (2)
Surgical treatment 7 (8)
Surgical debridement 3 (3)
Surgical debridement and establishment
of internal osteosynthesis device
4 (4)
Arthritis 12 (13)
Medical treatment only 5 (5)
Surgical treatment 7 (8)
Surgical debridement 7 (8)
Surgical debridement and establishment




Medical treatment only 5 (5)
Surgical treatment 37 (40)
Surgical debridement 21 (23)
Surgical debridement and establishment
of internal osteosynthesis device
1 (1)
Amputation 18 (19)
Osteoarticular infection with orthopaedic device 33 (35)
Vertebral osteomyelitis 3 (3)
Medical treatment only 0
Surgical treatment 3 (3)
Surgical debridement without removal 0
Osteosynthesis removal and
implantation of new device
3 (3)
Prosthetic joint 14 (15)
Medical treatment only 1 (1)
Surgical treatment 13 (14)
Surgical debridement without removal 6 (6)
One-stage exchange strategy 0
Two-stage exchange strategy 7 (8)
Amputation 0
Internal osteosynthesis device infection 17 (18)
Medical treatment only 0
Surgical treatment 17 (18)
Surgical debridement without removal 1 (1)
Osteosynthesis removal 15 (16)
Osteosynthesis removal and
implantation of new device
0
Amputation 1 (1)
TABLE 3. Clinical outcome of 93 cases of bone and joint
infection due to Streptococcus species
Characteristic Value
Remission at 1 year after end of treatment 76 (82)
Death 7 (8)
During treatment period 4 (4)
After end of treatment 3 (3)
Causes of death
Death by infection 1 (1)
Death by cancer 3 (3)
Death by acute respiratory distress syndrome
caused by severe pneumonia
2 (2)
Death by suicide 1 (1)
Unfavourable clinical outcomes 16 (17)
Death by infection 1 (1)
Failure during treatment 8 (9)
Median time to failure 141 days
Evolution
Remission after further ATB 1 (1)
Failure after further treatment 4 (4)
Wound care only 2 (2)
Wound care with suppressive antibiotic therapy 2 (2)
Remission after osteosynthesis




Median time to relapse (after end of treatment) 218 days




Median time to amputation (from date of infection) 447 days
Type of infection
Diabetic foot 11 (12)
Ischemic foot 1 (1)
Chronic wound of foot 1 (1)
Chronic osteitis 5 (5)
Joint prosthesis infection 1 (1)
Delay of amputation
Before starting antibiotic treatmenta 3 (3)
Diabetic foot 3 (3)
During antibiotic treatment 10 (11)
Neoplastic transformation 1 (1)
Ischemic foot 1 (1)
Diabetic foot 5 (5)
Chronic osteitis 2 (2)
Joint prosthesis infection 1 (1)
Treatment failure 0
After end of antibiotic treatmenta 7 (8)
Neoplastic transformation 0
Ischemic foot 0
Diabetic foot 4 (4)
Chronic osteitis 3 (3)
Joint prosthesis infection 0
Failure to treatment 2 (2)
Relapse 5 (5)
Reason for amputation
Treatment failure 2 (2)
Relapse 6 (6)
Other 11 (12)
Neoplastic transformation of foot osteitis 1 (1)
Ischemic foot 1 (1)
Diabetic foot 6 (6)
Chronic osteitis 2 (2)
Joint prosthesis infection 1 (1)
aUnfavourable clinical outcome was included in cases of treatment failure and
relapse.
Data are presented as n (%) unless otherwise indicated.
NMNI Seng et al. Infections with streptococcal involvement 13device infection were treated by surgery, including 15 cases of
osteosynthesis removal, one case of surgical debridement
without removal and one case of amputation (Table 2).
Follow-up and clinical outcomes
A total of 93 patients were evaluated during an average follow-
up time of 22 months (±15 months; range, 1–58 months).
Remission at 1 year after the end of treatment was recorded in
76 patients (82%). Sixteen patients (17%) had an unfavourable
clinical outcome related to infection, including one death, eight
cases (9%) of failure to treat and seven cases (8%) of relapse.
The median time to failure to treat was 141 days after starting
treatment, and the median time to relapse was 218 days after© 2016 The Authors. Published by Elsevier Ltd on beha
This is an open access articthe end of treatment. The clinical outcome of failure and
relapsed cases is detailed in Table 3.
Twenty patients (22%) had an unfavourable functional
outcome, including 19 amputations and one arthrodesis.
Amputation was performed in 19 patients (20%), with a median
time to amputation from date of infection of 447 days. Diabetic
foot was the main type of streptococcal bone and joint infec-
tion, leading to amputation in 11 cases, followed by chroniclf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 12, 8–17
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 4. Unfavourable clinical outcome and prognostic







Male sex 3.25 — — 0.450
Comorbidities and risk factors
Tobacco use 0.62 — — 0.750
Alcoholism 2.96 — — 0.238
Chronic liver disease 2.65 — — 0.189
Peripheral neuropathy 5.25 1.56 17.71 0.009
Peripheral arterial disease 4.55 1.39 14.93 0.019
Diabetes mellitus 4.07 1.23 13.49 0.031
Malignancy 0.40 — — 0.683
Immunodeﬁciency 0.64 — — 1.000
Inﬂammatory rheumatism 1.36 — — 0.584
Pneumonia 5.69 — — 0.291
Chronic wound 2.55 — — 0.147
Open fracture 0.75 — — 1.000
Closed fracture 1.36 — — 0.733
Orthopaedic device 1.01 — — 1.000
Prosthetic joint — — — 0.114
Type of infection
Arthritis — — — 0.201
Osteitis without
orthopaedic device
3.75 1.08 13.06 0.041
Vertebral osteomyelitis 0.88 — — 1.000
Prosthetic joint infection — — — 0.114
Osteosynthesis
device infection
1.19 — — 0.726
Vertebral osteosynthesis
device infection
— — — 1.000
Localization of infection
Sternoclavicular — — — 1.000
Shoulder — — — 1.000
Wrist — — — 1.000
Hand — — — 1.000
Vertebra 0.56 — — 1.000
Pelvis — — — 1.000
Hip 0.64 — — 1.000
Femur — — — 0.157
Knee — — — 0.115
Tibia 2.60 — — 0.223
Ankle 0.75 — — 1.000
Foot 1.70 — — 0.371
Multiple localization — — — 0.584
Streptococcus species
acidominimus — 1.000
agalactiae 1.12 — — 1.000
anginosus — — — 0.344
constellatus 1.62 — — 0.628
dysgalactiae 5.40 1.41 20.65 0.020
equinus — 1.000
intermedius — 1.000
14 New Microbes and New Infections, Volume 12 Number C, July 2016 NMNIosteitis in ﬁve cases, ischemic foot in one case, a chronic foot
wound in one case and joint prosthesis infection in one case.
Three amputations were performed before initiating antibi-
otic treatment; all were diabetic foot infections. Ten amputa-
tions were performed during antibiotic treatment involving
diabetic foot infection in ﬁve cases, chronic osteitis in two
cases, neoplastic transformation in one case, ischemic foot in
one case and prosthetic joint infection in one case. Seven am-
putations were performed after the end of antibiotic treatment
involving relapses in six cases, diabetic foot infection in four
cases, chronic osteitis in three cases and failure to treat in two
cases. One patient had two amputations: one before treatment
and one after the end of antibiotic treatment for relapse
(Table 3).
Seven patients (8%) died, including four during the treatment
period and three after the end of treatment. One patient died
of infection; two died of acute respiratory distress syndrome
related to severe pneumonia; three deaths were related to
cancer; and there was one case of suicide.
In the univariate analysis (Table 4), ﬁve signiﬁcant prognostic
factors associated with an unfavourable clinical outcome were
identiﬁed, including peripheral neuropathy (odds ratio (95%
conﬁdence interval): 5.25 (1.56–17.71) p 0.009), peripheral
arterial disease (4.55 (1.39–14.93) p 0.019), diabetes mellitus
(4.07 (1.23–13.49) p 0.031), location in the femur (relative risk
26 (2.91–232.62) p 0.0036), location in the foot (relative risk 2.10
(1.01–4.37) p 0.0475), osteitis without an orthopaedic device
(3.75 (1.08–13.06) p 0.041) and infection caused by S. dysgalactiae
(5.40 (1.41–20.65) p 0.020) (Table 4). We did not identify any
speciﬁc factors in the multivariate analysis adjusted for diabetes
mellitus, location in the foot and polymicrobial bone and joint
infection. The Kaplan-Meier curve showed that bone and joint
infections caused by S. dysgalactiae have worse clinical outcomes
than other streptococcal species (Fig. 3).massiliensis — 1.000
mitis 0.88 — — 1.000
oralis 1.85 — — 0.502
pneumoniae — — — 0.344
pyogenes — — — 1.000Discussion
salivarius — — — 1.000
sanguinis — — — 1.000
Polymicrobial infection 2.44 — — 0.238
Antibiotic
Amoxicillin 0.84 — — 0.774
Third-generation
cephalosporin
1.01 — — 1.000
Ticarcillin–clavulanate 0.50 — — 1.000
Piperacillin–tazobactam 0.73 — — 1.000
Imipenem–cilastatin — — — 1.000
Rifampicin 0.99 — — 1.000
Doxycycline 5.69 — — 0.291
Aminoglycoside 0.64 — — 1.000
Clindamycin 2.76 — — 0.101
Fluoroquinolones 2.05 0.305
Cotrimoxazole 2.42 0.167
Vancomycin and teicoplanin — — — 0.115
Hyperbaric oxygen therapy 0.73 — — 1.000
Surgical treatment — — — 0.201Here we report a large series of streptococcal bone and joint
infections identiﬁed at the species levels, representing 2.4% of the
bone and joint infections followed up in our reference centres
over the past 5 years. Streptococcal bone and joint infections,
which are less common than staphylococci, were reported to be
approximately 2% to 15.4% in the literature [1,2,34–36]. As for
the cases of staphylococci, strategy and treatment approaches
have improved themanagement over the last 20 years. There are
now speciﬁc treatment protocols dedicated to speciﬁc staphy-
lococcal species [37]. However, no similar approaches exist for
streptococcal bone and joint infections.© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 12, 8–17
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
FIG. 3. Unfavourable clinical outcome according to bone and joint infection caused by Streptococcus dysgalactiae vs. other streptococcal species by
Kaplan-Meier test.
NMNI Seng et al. Infections with streptococcal involvement 15Streptococcal bone and joint infections have been reported
to be frequent in women (56–62%) [6,15], which contrasts
with our ﬁnding that only 17% of the cases in our study involved
women. Men were affected more often than women, and
therefore the demographic characteristics of streptococcal
bone and joint infection in our patients were similar to those
found in bone and joint infection caused by staphylococci or
anaerobic bacterial bone and joint infection [26,38].
Numerous risk factors have previously been associated with
bone and joint infections, including malignancy, immunodeﬁ-
ciency, diabetes mellitus, age over 65 years, chronic alcoholism,
inﬂammatory rheumatism [3,4,6,31], diabetic foot and decubi-
tus ulcers, especially for osteomyelitis [31]. Most cases of
streptococcal bone and joint infection in our study presented a
comorbidity or a risk factor at a rate higher than in previous
studies (36–38%) [6,15]. This ﬁnding could explain the signiﬁ-
cant rate of amputation (20%), death (8%) and unfavourable
clinical outcomes (17%). Beyond the well-known comorbidity
and risk factors for streptococcal bone and joint infection, we
observed a signiﬁcant association between haematologic ma-
lignancy and infection with S. agalactiae (p 0.023) and solid
cancer and infection with S. constellatus (p 0.016). This© 2016 The Authors. Published by Elsevier Ltd on beha
This is an open access articobservation has been poorly reported in previous studies. We
have also identiﬁed three main comorbidities that were signif-
icantly associated with unfavourable clinical outcomes: periph-
eral neuropathy (p 0.009), peripheral arterial disease (p 0.019)
and diabetes mellitus (p 0.031).
Most of our cases of streptococcal orthopaedic device
infection (88% of the 33 cases) were chronic infections
occurring after 1 month of implantation, as reported in previ-
ous studies [8,15]. The identiﬁcation of streptococcal isolates
from blood cultures in our series (14% of cases) was less
frequent than that in the literature (27–72%).
We identiﬁed 14 species of 100 streptococcal isolates involved
in bone and joint infection almost exclusively by MALDI-TOFMS.
Only three isolates (S. agalactiae, S. pneumoniae and S. anginosus)
required molecular identiﬁcation. S. agalactiae was the most
frequent species (37% of cases) in our study; it was observed in
12% to 75% of cases in previous studies [6,10,12,15,32,33,39].
S. pneumoniae is known as a pathogen of arthritis without an or-
thopaedic device [6] and vertebral osteomyelitis [12]. Never-
theless, we have identiﬁed four cases of pneumococcal prosthetic
joint infection and one case of orthopaedic device infection; these
types of infection are poorly reported in the literature.lf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 12, 8–17
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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joint infection in our study, S. dysgalactiae was the second
streptococcal species (12%). Only a few cases of bone and joint
infection caused by S. dysgalactiae (formally group C and/or
group G streptococci) have been reported [6,10,12,39–41].
The cases of streptococcal osteitis are located mainly in the
foot [31]; 64% of our streptococcal osteitis cases (42 cases)
were located in the foot, including 17 diabetes mellitus patients
(63%). Diabetic foot osteomyelitis infections are polymicrobial
in more than 50% of cases [32,33], and these infections
frequently occur with Streptococcus species more than with
S. aureus [31,33], although coinfection with S. aureus or Pseu-
domonas aeruginosa has been reported [32,33].
In our study, polymicrobial foot osteomyelitis was identiﬁed
in 29 of the 59 cases of polymicrobial bone and infections with
streptococcal involved. The polymicrobial nature of foot oste-
omyelitis in diabetic foot infection and the role of streptococci
have been clearly demonstrated in a study of the microbiome of
diabetic foot osteomyelitis using conventional culture tech-
niques and 16S rRNA sequencing [42]. Besides diabetic foot
osteomyelitis, the polymicrobial nature of nondiabetic foot
osteomyelitis including foot osteomyelitis in patients with pe-
ripheral arterial disease, peripheral neuropathy and chronic
wound were poorly reported. We have identiﬁed that, except
for diabetic foot osteomyelitis with streptococcal involved
(seven cases) that were mixed infection, 85% of 13 nondiabetic
foot osteomyelitis with streptococcal involved were mixed
infection. To conﬁrm these results, further study is required to
elucidate the role and signiﬁcance of streptococci in poly-
microbial foot osteomyelitis with streptococcal involvement.
In our study, foot osteitis was associated with polymicrobial
infection in 93% of cases and coinfection with S. aureus in 38% of
cases. Polymicrobial infections represent a signiﬁcant risk factor
for limb loss [32], especially when associated with S. aureus strains
resistant to antibiotics [32]. These infections were identiﬁed as a
prognostic factor associated with relapse in our study. The rate of
unfavourable clinical outcome was high (17%) despite the very
low rate of streptococcus isolate–reduced susceptibility to
amoxicillin (1%) in our study. We think that antibiotic treatment
regimens need to be further investigated in future studies,
particularly for each well-deﬁned Streptococcus species.ConclusionStreptococcal bone and joint infections are rare and are usually
polymicrobial. Most streptococcal orthopaedic device in-
fections were chronic infections. Surprisingly, the proportion of
unfavourable clinical outcomes and amputations related to
infection was considerable despite of low rate of antimicrobial© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceresistance. Therefore, therapeutic failure compared to staphy-
lococci infection is not due to multidrug-resistant microbial
strains or to the selection of resistant strains during therapy;
rather, it seems to depend on the Streptococcus species
involved. Our study clearly determined that some prognostic
factors, such as S. dysgalactiae, were associated with unfav-
ourable clinical outcomes.AcknowledgementsThe authors thank C. Leautier, Y. Russo and C. Peruffo for their
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Antimicrobial Agents and Chemotherapy and 28th International
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